当地时间6月30日,制药公司艾伯维宣布,将以21亿美元的价格收购体内CAR-T细胞疗法开发商Capstan Therapeutics,以扩大自身免疫性疾病疗法的产品线。自2023年艾伯维的明星药物阿达木单抗(修美乐)专利到期以来,艾伯维已斥资超过200亿美元进行大手笔收购。该公司正在与Vertex、百时美施贵宝(BMS)等制药巨头在自身免疫药物领域展开竞争。艾伯维最新押注的Capstan基于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.